Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) ...
RCT-2100 is under clinical development by Recode Therapeutics and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition ...
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug ...
It is administered through inhalational route. The drug candidate is developed as a nebulized therapy. It was under development for primary ciliary dyskinesia (PCD), tracheostomy, cystic fibrosis, ...
FRIDAY, Dec. 20, 2024 (HealthDay News) -- Most children with likely primary ciliary dyskinesia (PCD) have asthma, according to a research letter published online Dec. 9 in JAMA Network Open.
FRIDAY, Dec. 20, 2024 (HealthDay News) -- Most children with likely primary ciliary dyskinesia (PCD) have asthma, according to a research letter published online Dec. 9 in JAMA Network Open. Joe Zein, ...
Anxiety dysphagia is one of many physical and medical causes of dysphagia. Dysphagia is the medical term for difficulty when swallowing. Swallowing is a complex process. It involves coordination from ...